Emmes Group

92 Natoma St
San Francisco CA 94105
Reviews
{{::location.tagLine.value.text}}

Sponsored Topics

Opening Hours

  • Mon: 9am-5pm
  • Tue: 9am-5pm
  • Wed: 9am-5pm
  • Thu: 9am-5pm
  • Fri: 9am-5pm

See a problem? Let us know!
Emmes Group is an 18 year old consulting firm with offices in Boston and San Francisco. Emmes Group is a strategic business development, assessment and planning organization specializing in the support of firms engaged in the technology, internet, biotechnology and pharmaceutical industries. Our partners have over 50 years of combined experience in serving technology, internet and healthcare companies. Our client list is an impressive list of some of the leading companies in the world. Mr. Weiner has over 30 years of successful experience in general management, business development, marketing, market research and technical sales. He has contributed significantly in all the operational and strategic support roles he has filled for such companies as 3M, Bio-Rad Laboratories, Millipore, and Waters, and while consulting for: Bayer, Bristol-Myers Squibb, Bayer, Genzyme, Haemonetics, Hewlett-Packard, Beckman, Perkin-Elmer, Varian, Shimadzu, Mettler-Toledo, PE Applied Biosystems, and dozens of other major corporations worldwide. Mr. Schroeder has over 25 years of successful experience in general management, technical R&D management, marketing, corporate finance and business development. Mr. Schroeder has contributed to the success of companies such as @POS, Dow Chemical, Immunex, Medicine Planet, Cyrano Sciences, Gamera Bioscience, MetaXen, Vistagen, Bethesda Pharmaceuticals, Acacia Biosciences, Maxim Biotech, Invivogen, Optigon Technology, Primex Physics International, Health4her.com, eTradeVillage.com, RapidReceipt.com, NH Ventures and the Ohio State University Office of Technology Transfer. Mr. Peltzman has thirty plus years of business experience in companies spanning a spectrum of health care technologies from biopharmaceuticals to medical devices and diagnostics. From 1984 until 1991, he helped start and served as President and CEO of Applied bioTechnology, Inc., whose cancer business was sold to OSI Pharmaceuticals (OSIP NASDAQ; a.k.a. Oncogene Science). In 1991, he became Chief Operation Officer of the consolidated entity; from 1994 through 1997, he served as president and COO of OSI Pharmaceuticals and remained on its Board of Directors through 1999. From 1986 to 1990, Mr. Peltzman also was President of Oncogenetics Partners, a Joint Venture between Applied bioTechnology and E.I. du Pont de NeMours and Company, which focused on development of products relating to the prevention, treatment, and diagnosis of cancer. From 1980 to 1984, Mr. Peltzman held a number of senior executive positions with Millipore, and for the ten years preceding his position at Millipore, was with Corning's Medical businesses specializing in blood gas analysis. During the past several years he has been involved in several small, healthcare, and technology companies as their interim CEO and/or COO. Mr. Peltzman is active in TEC, a global organization of 6500 CEO's. Dr. Hsiung has broad experience in operations, business development as well as venture capital investments in the biopharmaceutical industry. Her responsibilities and achievements have included basic research in molecular and cellular biology, establishment and management of a tissue culture facility, licensing and technology assessment, project management, GMP pilot plant design, and development and introduction of a research detection kit. Dr. Hsiung's investment experience included a role as a special advisor to the GeneChem Technologies Venture Fund for two years. Dr. Hsiung's major strengths include strong analytical command, effective interpersonal skills, in-depth and extensive knowledge of the biopharmaceutical business, coupled with solid interviewing and analysis skills. Dr. Hsiung has a solid and successful track record of establishing new functions and procedures, and developing new business in many life science and technical start-up venture companies. Dr. Hsiung is the author of 26 publications abstracts; 4 US patents, and 2 US patent applications. Charles Keough has over 20